Preliminary First Nine Months 2019 Key Financials
Revenues:EUR 1.38million (growing by approximately 16% compared to EUR 1.19million in the nine months ended September 30, 2018).
Order Volume:Almost EUR 3.4millionin commercial ordervolume committed and received by Curetis and Ares Geneticsin 2019 year-to-date, including orders for Unyvero instruments and cartridges, Ares Genetics’ laboratory and advanced bioinformatics services, as well as compensations for access to certain rights. Therefore, order volumes have more than tripled compared toEUR 1.1 million in the same period of 2018.
Cash and cash equivalents:EUR 3.05 millionas of September 30, 2019 (vs. EUR 10.28millionas of December 31, 2018). Net cash burn in the first nine months ended September 30, 2019,was EUR -7.23million, i.e. a reduction by about 34.7% compared to a cash burn of EUR 11.07 million in the first nine months 2018. This was mainly the result of the successful implementation of the restructuring measures as well as financing cash inflows from EIB and Yorkville. Curetis will now have access to at least US$ 4 million under the interim financing facility in the coming months towards the closing of the business combination